Rapid Genomic Testing Helps Children with Severe Epilepsy
Researchers studied the effects of rapid genomic testing on children who were seriously ill and had severe epilepsy.
This hub covers pediatric epilepsy in infants, kids, and teens, including diagnosis, syndromes, development, school plans, and safety. New studies translated into clear takeaways for parents.
Usually when two appropriate medications haven’t controlled seizures.
Many families benefit and it depends on seizure frequency, medications, and learning needs.
Often yes, with smart precautions. Ask your neurologist or epileptologist about your child’s specific risks.
Clusters, prolonged seizures, breathing trouble, new weakness, or major regression.
Researchers studied the effects of rapid genomic testing on children who were seriously ill and had severe epilepsy.
Researchers studied how neurocognitive issues, behavior problems, and the treatment process affect stress levels in parents of children with epilepsy.
Researchers studied the relationship between specific genetic variations in the SCN1A gene and resistance to sodium valproate, a common epilepsy medication, in children.
Researchers studied how cognitive function is affected in children with epilepsy, particularly those who might need surgery.
Researchers conducted a study to explore the use of a secure digital tool for sharing videos of suspected seizures in children.
Researchers conducted a study to understand how effective first-line antiseizure medications (ASMs) are for children newly diagnosed with epilepsy.
Researchers conducted a study to examine the experiences and outcomes of pregnant individuals with epilepsy.
Researchers investigated the use of intravenous (i/v) levetiracetam (LEV) as a first-line treatment for patients experiencing non-convulsive status epilepticus (NCSE), a serious condition where seizures occur without noticeable convulsions.
Researchers conducted a study to compare the effectiveness and safety of two medications, levetiracetam and sodium valproate, in treating children aged 1 to 16 years who were experiencing refractory generalized convulsive status epilepticus.